ArticleBreast cancer (Dove Medical Press)2017
Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site.
Article in Breast cancer (Dove Medical Press), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- BoneCoT: multicentre validation of a whole-body skeleton foundation model for bone metastases guided by clinician-derived chain of thought.Nature biomedical engineering · 2026Article
- Metastatic Breast Cancer Presenting as an Organizing Pneumonia Pattern on Chest CT: A Case Report.Cureus · 2026Article
- Schwannoma of the Appendix Mimicking a Metastatic Breast Cancer:Sultan Qaboos University medical journal · 2025Article
- Breast biomarkers evolution between primary and distant metastasis: incidence and significance.Histopathology · 2025Article
- Article
- The changes of subtype markers between first and second primary breast cancers.Cancer medicine · 2023Article
- Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer.Scientific reports · 2022Article
- Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients.European journal of breast health · 2022Article
- Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.PloS one · 2022Article
- The rate of estrogen receptor-conversion associated with tumor progression in estrogen receptor-positive breast cancer patients following adjuvant Tamoxifen administration.Cancer reports (Hoboken, N.J.) · 2022Article
- Review
- Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer.Therapeutic advances in medical oncology · 2021Article
- The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.Asian Pacific journal of cancer prevention : APJCP · 2020Observational
- The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients.OncoTargets and therapy · 2020Article
- Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications.Cancer management and research · 2020Review
- Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.Oncotarget · 2019Article
- Breast Carcinoma Metastasis to the Medial Rectus Muscle: Case ReportTurkish journal of ophthalmology · 2019Article
- Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.Translational oncology · 2019Article
- Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Prognostic significance of heparanase expression in primary and metastatic breast carcinoma.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions.
methodsWe performed a retrospective review of paired biomarkers from primary breast cancers compared to first reported and subsequent metastases from 103 patients with breast cancer. The estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu status were reported at all three time points. In addition, hormone, cytotoxic, and targeted treatments were recorded for primary and metastatic disease, and survival was determined.
resultsBetween the primary and first metastases, discordance rates for ER, PR, and HER-2/neu were 15.8%, 33.7%, and 14.3%, respectively. There was discordance between the first and second metastases for the ER receptor in 18.8%, PR receptor in 19.8%, and HER-2/neu in 10.7%. Overall, there was discordance between the primary tumor and either the first or second metastases for ER in 27.7%, PR receptor in 40.7%, and HER-2/neu in 19.6% of cases. Discordance of either ER or PR affected survival, with worse survival experienced by those patients with all three hormone receptors remaining negative, and intermediate survival reported for those with discordant tumors (ER χ
conclusionThis study demonstrated that continued metastatic disease evolution may be associated with different tumor biology and that studies of metastatic lesions appear warranted, especially if targeted therapy is an option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.